| Date | Title | Description |
| 16.03.2026 | Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026 | Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026
Mon, Mar 16, 2026 09:00 CET Report this content Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be prese... |
| 09.03.2026 | Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial | Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial
Mon, Mar 09, 2026 10:33 CET Report this content MASCOT is a first-of-its-kind, Phase 3 trial supporting the development of amlenetug, an investigational th... |
| 23.02.2026 | NICE Recommends TEPKINLY[®] ▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy | NICE Recommends TEPKINLY[®] ▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy
Mon, Feb 23, 2026 10:51 CET Report this content
E... |
| 14.11.2025 | Medicxi Closes €500 Million Fund To Advance Asset-Centric Biotech Innovation | Medicxi announced the close of its €500 million Medicxi V vehicle, reinforcing the firm’s position as a major European life sciences investor and adding significant capital to expand its long-standing asset-centric company creation strategy... |
| 03.11.2025 | The Billion-Dollar Biology of Oncology: What Really Drives Pharma’s Appetite? | By Jonathan Tobin, Partner – Brandon Capital
Plenty is written about the trends in dollars and modalities being invested in oncology by VCs. But equally important are the exits, and for early-stage investors M&A is especially important.... |
| 24.10.2025 | Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore | The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older.
SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- ... |
| 02.10.2025 | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025 | Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 20251-3
MSA is a rar... |
| 02.10.2025 | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025 | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025
Thu, Oct 02, 2025 09:00 CET Report this content Details of the Phase 3 M... |
| 30.09.2025 | EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction | EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
Tue, Sep 30, 2025 09:15 CET Report this content
Genmab has entered into a definitive agreement to acquire Merus in an all-cash tra... |
| 29.09.2025 | Genmab to Acquire HBM Portfolio Company Merus for USD 8 billion in Cash | HBM Healthcare Investments, a leading investor in global healthcare companies, announces that its listed portfolio company, Merus (Nasdaq: MRUS), has entered into a transaction agreement with Genmab (Nasdaq: GMAB). Genmab intends to acquire... |
| 29.09.2025 | European stocks close higher as pharma giants AstraZeneca and GSK notch gains | Stocks listed in Europe closed higher on Monday, as investors monitored the impact of a potential U.S. government shutdown later in the week.
The pan-European Stoxx 600 provisionally ended up around 0.34%, with most sectors and major bourse... |
| 29.09.2025 | Датская Genmab покупает нидерландскую фармкомпанию Merus за $8 млрд | Genmab выкупит акции Merus по цене $97 за штуку наличными, говорится в совместном заявлении компаний в понедельник. Это примерно на 41% выше цены закрытия акций Merus, котирующихся в США, по состоянию на 26 сентября. Ранее Bloomberg News со... |
| 28.09.2025 | S&P 500 closes higher as AI leader Nvidia rebounds, EA surges on takeover | The S&P 500 rose on Monday as Wall Street regained some of its footing after a week in which the artificial intelligence trade lost a bit of steam.
The broad market index climbed 0.26% to finish at 6,661.21, and the Nasdaq Composite adv... |
| 04.09.2025 | AI Governance as Competitive Capability: The Pioneering Work of Sumesh Nair in Biopharma | Created by Carl Williams
Published: Sep 04 2025, 00:41 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 06.08.2025 | Quantifying the ROI of Compliance: Sumesh Nair on Architecting Risk-Based AI Validation for Modern Clinical Trials | Share
Share
Share
Share
Email
For any new therapy to reach the patients who need it, it must first navigate a formidable and complex global regulatory landscape. In the life sciences industry, this landscape is built upon a foundational set... |
| 22.07.2025 | Society for Immunotherapy of Cancer Forward Fund Announces 2025 Fellowship Recipients, Awarding $430,000 to Support Promising Early Career Researchers | SITC Forward Fund
Demonstrating its commitment to advancing immunotherapy and supporting the next generation of scientific leaders, the Society for Immunotherapy of Cancer (SITC) Forward Fund is proud to announce the recipients of its 2025 ... |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con... |
| 09.05.2025 | Winter Wellness: A Guide for Seniors to Thrive in Cold Weather | Winter is a double-edged sword. It brings beauty and wonder, but it also poses challenges, especially for seniors. As the temperature drops, the risks rise. Icy sidewalks become treacherous, and the cold can seep into homes, leading to heal... |
| 08.05.2025 | Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston | Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston
Thu, May 08, 2025 08:00 CET Report this content
H. Lundbeck A/S (Lundbeck) will present ... |
| 07.05.2025 | The Landscape of Corporate Acquisitions: Saga Pure ASA's Bold Move | In the world of corporate acquisitions, the stakes are high, and the players are strategic. Saga Pure ASA recently made headlines with its mandatory offer to acquire all outstanding shares of S.D. Standard ETC Plc. This move is not just a t... |
| 07.05.2025 | The Pulse of Progress: DNB's First Quarter Presentation and BioStock Global Forum | In the world of finance and innovation, timing is everything. Two significant events loom on the horizon, each promising to shape the landscape of their respective industries. DNB's first quarter presentation and the BioStock Global Forum a... |
| 06.05.2025 | Pfizer, Novo, Novartis and Genmab are coming to BioStock Global Forum, are you? | Pfizer, Novo, Novartis and Genmab are coming to BioStock Global Forum, are you?
Tue, May 06, 2025 14:52 CET Report this content
Take the opportunity to connect with top life science investors and innovators during this rewarding two-day eve... |
| 04.04.2025 | New Chromatography Data Platform Wins Bio-IT World Award for Genmab and Genedata | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Genedata Chromatics revolutionizes separation sciences by streamlining chromatog... |
| 12.03.2025 | The Future of Neurorehabilitation: Innovations and Breakthroughs | In the world of healthcare, innovation is the lifeblood that keeps the industry thriving. Recently, two remarkable developments have emerged in the realm of neurorehabilitation. One is a groundbreaking software startup that harnesses augmen... |
| 10.03.2025 | Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan | VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Mu... |
| 10.03.2025 | Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan | Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
Mon, Mar 10, 2025 09:01 CET Report this content
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designati... |
| 12.02.2025 | Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA | Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
Wed, Feb 12, 2025 09:00 CET Report this content
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug,... |
| 17.12.2024 | Swiss investors shine in Forbes Midas list |
Every year, Forbes' Midas List recognises the top 25 European investors. Being included on the list is considered a definitive accolade in the investor community – similar to being nominated for the Ballon d'Or in football, for example.
Mi... |
| 27.11.2024 | Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy | Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy
Wed, Nov 27, 2024 08:00 CET Report this content
MASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the ... |
| 27.09.2024 | Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders | Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders
Fri, Sep 27, 2024 14:00 CET Report this content
Lundbeck advances its commitment to addressing the... |
| 08.07.2024 | Danish pole position among best Nordic life science stocks in H1 | Danish pole position among best Nordic life science stocks in H1
Mon, Jul 08, 2024 07:45 CET Report this content
The first six months of 2024 have passed and it is time to swap the ergonomically designed office chair for a sunbed At BioStoc... |
| 21.03.2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
| 17.03.2024 | Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year | Economy Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year
George Glover
2024-03-17T08:31:02Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
F... |
| 13.03.2024 | Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab | - |
| 13.03.2024 | Passing of Genmab A/S’ Annual General Meeting | - |
| 13.03.2024 | Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | - |
| 17.04.2023 | Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | Genmab A/S and argenx announced that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeut... |
| 26.01.2022 | Genmab A/S : Supplier Code of Conduct | Genmab Global Supplier Code of Conduct
Introduction
Genmab is focused on the creation and development of innovative and differentiated antibody products, with the aim of improving the lives of cancer patients. At Genmab we seek to establish... |
| 12.01.2022 | Genmab A/S : Human Rights Policy | Human Rights Commitment
As a global biotechnology company committed to social responsibility and sustainability, Genmab strives to comply with all laws, regulations, and standards applicable to the conduct of its business.
While governments... |
| 13.12.2021 | Genmab A/S : Corporate Social Responsibility Policy | Corporate Social Responsibility Policy
Genmab is committed to building a sustainable and socially responsible biotech, one whose actions reliably benefits patients, stakeholders, and society as a whole.
Our approach to Corporate Social Resp... |
| 22.09.2021 | Genmab A/S : Articles of association dated September 21, 2021 – English | (Unauthorized English translation)
(September 21, 2021)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Co... |
| 22.09.2021 | Genmab A/S : Investor Presentation - September 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
September 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward lookin... |
| 18.08.2021 | Genmab A/S : Articles of Association dated August 17, 2021 – English | (Unauthorized English translation)
(August 17, 2021)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Compa... |
| 11.08.2021 | Genmab A/S : Investor Presentation - August 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
August 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward looking s... |
| 08.07.2021 | Genmab A/S : Articles of Association dated July 06, 2021 – English | (Unauthorized English translation)
(July 6, 2021)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Company ... |
| 01.07.2021 | Genmab A/S : Articles of Association dated June 22, 2021 – English | (Unauthorized English translation)
(June 22, 2021)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Company... |
| 11.06.2021 | GENMAB A/S
Genmab A/S : Investor Presentation - June 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
June 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward looking sta... |
| 05.05.2021 | GENMAB A/S
Genmab A/S : Investor Presentation - May 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
May 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward looking stat... |
| 27.04.2021 | GENMAB A/S
Genmab A/S : Articles of association dated April 13, 2021 – English | (Unauthorized English translation)
(April 13, 2021) (II)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the C... |
| 27.04.2021 | Genmab A/S : Articles of association dated April 13, 2021 – English | (Unauthorized English translation)
(April 13, 2021) (II)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the C... |
| 09.04.2021 | GENMAB A/S
Genmab A/S : Investor Presentation - April 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
April 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward looking st... |
| 30.03.2021 | NOVARTIS AG
Novartis : receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis | There are more than 1 million people living with multiple sclerosis (MS) in Europe1, Kesimpta® (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that combines powerful efficacy and favorable s... |
| 23.02.2021 | GENMAB A/S
Genmab A/S : Compensation Report 2020 | 1
Genmab Remuneration Report 2020
Compensation Report for 2020
Compensation Report for 2020,
Genmab A/S
CVR no. 2102 3884
LEI code 529900MTJPDPE4MHJ122
This Compensation Report for 2020 describes the details of the compensation of the Board... |
| 23.02.2021 | Genmab A/S : Compensation Report 2020 | 1
Genmab Remuneration Report 2020
Compensation Report for 2020
Compensation Report for 2020,
Genmab A/S
CVR no. 2102 3884
LEI code 529900MTJPDPE4MHJ122
This Compensation Report for 2020 describes the details of the compensation of the Board... |
| 23.02.2021 | GENMAB A/S
Genmab A/S : CSR Report 2020 - English | Corporate Social Responsibility 2020 Report
24 Risks Relating to CSR
Introduction & CEO Letter
Contents
2
3
4
5
6
8
Contents CEO Letter Highlights About Genmab
Our Commitment to Corporate Social Responsibility Our Response to COVID-19
E... |
| 23.02.2021 | Genmab A/S : CSR Report 2020 - English | Corporate Social Responsibility 2020 Report
24 Risks Relating to CSR
Introduction & CEO Letter
Contents
2
3
4
5
6
8
Contents CEO Letter Highlights About Genmab
Our Commitment to Corporate Social Responsibility Our Response to COVID-19
E... |
| 21.12.2020 | Genmab A/S : Articles of association dated December 15, 2020 – English | (Unauthorized English translation)
(December 15, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 71
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Com... |
| 21.12.2020 | GENMAB A/S
Genmab A/S : Articles of association dated December 15, 2020 – English | (Unauthorized English translation)
(December 15, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 71
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Com... |
| 11.11.2020 | GENMAB A/S
Genmab A/S : Articles of association dated November 10, 2020 – English | (Unauthorized English translation)
(November 10, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 71
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Com... |
| 11.11.2020 | Genmab A/S : Articles of association dated November 10, 2020 – English | (Unauthorized English translation)
(November 10, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 71
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Com... |
| 15.10.2020 | GENMAB A/S
Genmab A/S : Articles of association dated October 07, 2020 – English | (Unauthorized English translation)
(October 7, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 70
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Compa... |
| 30.09.2020 | GENMAB A/S
Genmab A/S : Articles of association dated September 29, 2020 – English | (Unauthorized English translation)
(September 29, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 69
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Co... |
| 21.08.2020 | J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in | J&J’s third-line multiple myeloma blockbuster Darzalex got the FDA green light for a new regimen to take another swing at the blood cancer — this time, in a cocktail with carfilzomib and dexamethasone.
The combination ... |
| 04.05.2020 | New Darzalex formulation wins FDA approval; Israeli biotech plans $50M IPO | → During the Covid-19 crisis, drugs that must be administered in hospital settings or take hours to be infused are seeing delayed uptake as health care facilities are filled to the brim with coronavirus patients. Cancer d... |
| 13.03.2020 | CureVac’s Ingmar Hoerr tells us why he returned to take on a pandemic; NGM loses a president | Ingmar Hoerr
On Tuesday, Ingmar Hoerr stood up from his seat at the head of CureVac’s board of directors meeting in Frankfurt, Germany and walked out the door.
For 18 years, Hoerr had led the company he founded, stewardin... |
| 29.05.2019 | Denmark’s Genmab files for $500M Nasdaq listing in US | The company is looking to raise $500 million in its US market debut, according to the Form F-1. Morgan Stanley is the lead book runner, joined by BofA Merrill Lynch, Guggenheim Securities, Jefferies and RBC Capital Markets.
The company’s le... |
| 08.05.2017 | Building an orphan pipeline, Horizon Pharma bags PhIII-ready rare disease drug in $145M buyout | Timothy P. Walbert
Eight months after a little-known subsidiary group named River Vision Development Corp. won a breakthrough therapy designation for its lead drug for a rare eye disease, Horizon Pharma $HZNP has swooped... |
| 11.08.2016 | Start small, think big: Genmab racks up a bispecific development deal with HIV specialist Gilead | Genmab is on a roll. The biotech has inked another high-profile collaboration deal — this time with Gilead — that will put its bispecific antibody tech to work on HIV therapies.
The deal starts small, with Gilead handing ove... |
| 26.07.2016 | Protocols: Booming Moderna adds staff, new clinical program; Lilly boasts of R&D gains | As promised, fast-growing Moderna has moved its second program into clinical development. The mRNA specialist now has mRNA 1440 and mRNA 1851, infectious disease vaccine candidates, in early stage studies. And there ... |
| 30.04.2012 | GSK leukemia treatment Arzerra filed for regulatory approval in Japan | The U.S. Food and Drug Administration approved ofatumumab, now called Arzerra, in 2009. Arzerra is the first commercialized drug to emerge from Denmark-based Genmab’s drug pipeline. Britain-based GSK, which has its U.S. headquarters in Rese... |
| 11.04.2002 | Genmab and Paradigm Therapeutics announce major alliance on discovery targets for human an... | Genmab and Paradigm Therapeutics announce major alliance on discovery targets for human an...
11-04-2002
Copenhagen, Denmark 11 April, 2002.
..Genmab A/S and the privately owned Cambridge, UK based Paradigm Therapeutics Ltd today announced ... |
| - | Four innovations that may shape cancer treatment | While significant progress has been made in the treatment of cancer, there is still a long way to go. Cancer has been the second leading cause of death among Americans for almost a decade.1 This year in the United States alone, it is estima... |
| - | Bioqube Ventures launches Bioqube Factory Fund I | June 10th – Hasselt/Brussels, Belgium – Bioqube Ventures announces today the first closing of Bioqube Factory Fund I, a new early stage venture capital fund focused on the development of therapeutic assets and technology platforms in Europe... |
| - | GSK leukemia treatment Arzerra filed for regulatory approval in Japan | Leukemia treatment Arzerra, developed by GlaxoSmithKline (NYSE:GSK) and drug partner Genmab (CSE:GEN), has been submitted for approval in Japan.
Arzerra has currently received regulatory approval in the United States and Europe to treat chr... |
| - | Transforming patients’ lives starts with innovating novel medicines and enabling access to them | It’s indisputable that developing new treatment options is a crucial component to helping people with cancer live better — but driving real, meaningful change requires much more than that.
While innovation in medicine is at an all-time high... |
| - | European stocks close marginally lower as markets digest U.S. data and BOE hike; mining firms down 3% | This is CNBC’s live blog covering European markets. |
| - | Denmark’s Genmab files for $500M Nasdaq listing in US | A Danish drugmaker is looking to list its shares on the Nasdaq.
Copenhagen-based Genmab said Tuesday that it had filed a Form F-1 with the Securities and Exchange Commission for a potential offering of shares on the US market, wherein it wo... |
